Bill > S3791

This bill, the Access to Prescription Digital Therapeutics Act of 2022, aims to provide coverage and payment for prescription digital therapeutics (PDTs) under the Medicare and Medicaid programs. PDTs are defined as FDA-cleared or approved products that primarily use software to prevent, manage, or treat medical conditions. The bill requires the Secretary of Health and Human Services to establish a payment methodology for PDTs under Medicare, including considerations like the actual list charge and weighted median payment rates. It also mandates the creation of product-specific billing codes and requires manufacturers to report payment rates, volumes, and user numbers. Additionally, the bill adds PDTs as a covered benefit under Medicaid.